Skip to main content

NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.

Publication ,  Journal Article
Callander, NS; Baljevic, M; Adekola, K; Anderson, LD; Campagnaro, E; Castillo, JJ; Costello, C; Devarakonda, S; Elsedawy, N; Faiman, M; Htut, M ...
Published in: J Natl Compr Canc Netw
January 2022

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with various plasma cell neoplasms, including multiple myeloma. These NCCN Guidelines Insights highlight some of the important updates/changes specific to the treatment of patients with multiple myeloma in the 2022 version of the guidelines.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

January 2022

Volume

20

Issue

1

Start / End Page

8 / 19

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Multiple Myeloma
  • Humans
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Callander, N. S., Baljevic, M., Adekola, K., Anderson, L. D., Campagnaro, E., Castillo, J. J., … Kumar, S. K. (2022). NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw, 20(1), 8–19. https://doi.org/10.6004/jnccn.2022.0002
Callander, Natalie S., Muhamed Baljevic, Kehinde Adekola, Larry D. Anderson, Erica Campagnaro, Jorge J. Castillo, Caitlin Costello, et al. “NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.J Natl Compr Canc Netw 20, no. 1 (January 2022): 8–19. https://doi.org/10.6004/jnccn.2022.0002.
Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, et al. NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw. 2022 Jan;20(1):8–19.
Callander, Natalie S., et al. “NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022.J Natl Compr Canc Netw, vol. 20, no. 1, Jan. 2022, pp. 8–19. Pubmed, doi:10.6004/jnccn.2022.0002.
Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, Costello C, Devarakonda S, Elsedawy N, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Liedtke M, Martin T, Omel J, Sborov D, Shain K, Stockerl-Goldstein K, Weber D, Berardi RA, Kumar R, Kumar SK. NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw. 2022 Jan;20(1):8–19.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

January 2022

Volume

20

Issue

1

Start / End Page

8 / 19

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Multiple Myeloma
  • Humans
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis